Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
22:03
Donald Trump states that it is time for Ukraine “to have a new leader who can reach an agreement” with Russia
21:43
Inter Milan return to the top of Serie A after a clear victory over Parma
21:24
Luca Niculescu, details about the governing program: “We are working intensively to finalize the governing program. We aim to identify solutions for increasing incomes, with priority given to pensioners with low pensions”
21:07
Paul Stănescu rejects rumors about leaving the PSD for AUR: “I have negotiated many things in my political life. However, I have never put my convictions on the negotiating table.”
20:33
Pope Leo XIV condemns the death penalty, while the US prepares to broadcast an execution live
See more news